



**ORIGINAL RESEARCH PAPER**

**General Medicine**

**CLINICAL MANAGEMENT OF HEMATURIA SECONDARY TO IFOSFAMIDE**

**KEY WORDS:** Hematuria, Ifosfamide, Cancer, Chemotherapy

<b>Echeverría Saavedra José Francisco</b>	Independent Investigator
<b>Meneses Chauca Milton Antonio</b>	Independent Investigator
<b>Calero Tipantuña Alejandra Elizabeth</b>	Independent Investigator
<b>Benítez Loaiza Rocío Cecibel</b>	Independent Investigator
<b>Corrales Tapia Alexander Michael</b>	Independent Investigator

**ABSTRACT** Hematuria, characterized by the presence of blood in urine, is a common side effect associated with the administration of ifosfamide, a widely used alkylating chemotherapeutic agent. This manuscript reviews the clinical management of hematuria secondary to ifosfamide, including its pathophysiology, risk factors, and current treatment strategies. The aim is to provide healthcare professionals with a comprehensive understanding of the condition and its management, thereby optimizing patient care and minimizing associated complications.

**1. INTRODUCTION:**

Ifosfamide is an integral component of chemotherapy regimens for various malignancies, including sarcomas, lymphomas, and germ cell tumors. Despite its efficacy in treating these malignancies, ifosfamide is notorious for inducing urological complications, particularly hematuria. The occurrence of hematuria can lead to dose reductions, treatment interruptions, and impaired patient quality of life.

**2. Pathophysiology of Ifosfamide-Induced Hematuria:**

The exact mechanisms underlying ifosfamide-induced hematuria are complex and not fully elucidated. However, it is widely believed that the primary contributor is the production of acrolein, a toxic metabolite of ifosfamide, in the renal tubules. Acrolein causes direct damage to the urothelium, resulting in inflammation, oxidative stress, and disruption of the normal barrier function of the urinary tract. This leads to hemorrhage and the subsequent presence of blood in urine.

**3. Risk Factors:**

Several factors influence the likelihood of developing ifosfamide-induced hematuria. High cumulative doses of ifosfamide, rapid infusion rates, and co-administration with other nephrotoxic agents, such as cisplatin, increase the risk. Patients with pre-existing renal impairment or a history of urological abnormalities are also more susceptible.

**4. Clinical Presentation:**

Ifosfamide-induced hematuria can range from microscopic hematuria detected on urinalysis to gross hematuria with clots. Patients may experience dysuria, urgency, and suprapubic discomfort. Regular monitoring of urine output and urinalysis is essential during treatment to promptly identify any changes and adjust management accordingly.

**5. Management Strategies:**

**5.1. Prevention:**

To minimize the risk of ifosfamide-induced hematuria, hydration is crucial. Aggressive intravenous hydration before and after ifosfamide administration can help dilute acrolein and reduce its contact with the urothelium. Mesna, a sulfhydryl compound, is often co-administered with ifosfamide to bind and detoxify acrolein, further mitigating its urotoxic effects.

**5.2. Symptomatic Management:**

For patients who develop hematuria despite preventative measures, symptomatic management is essential. Supportive care includes maintaining adequate hydration to flush out the urinary tract and provide relief from discomfort. Analgesics can alleviate pain associated with bladder irritation.

**5.3. Temporary Treatment Interruption:**

In cases of severe hematuria or clot formation, temporary interruption of ifosfamide treatment might be necessary. This allows time for the urothelium to heal and prevents further exacerbation of the condition.

**5.4. Urologic Consultation:**

Persistent or severe hematuria requires consultation with a urologist. Endoscopic evaluation, such as cystoscopy, may be performed to assess the extent of urothelial damage and rule out other causes of hematuria.

**5.5. Alternative Treatment Regimens:**

In cases where ifosfamide-induced hematuria is intolerable or recurrent, oncologists may consider alternative chemotherapy regimens that are less urotoxic or dose adjustments to minimize toxicity while maintaining therapeutic efficacy.

**6. CONCLUSION:**

Ifosfamide-induced hematuria is a challenging clinical issue that requires a multidisciplinary approach. Healthcare providers should be aware of the risk factors, pathophysiology,

and management strategies associated with this condition. A combination of preventative measures, supportive care, and urologic consultation can optimize patient outcomes and maintain the integrity of ifosfamide-based chemotherapy regimens. Further research is warranted to better understand the underlying mechanisms and develop more targeted interventions for this urological complication.

**7. Future Directions:**

While the current management strategies for ifosfamide-induced hematuria have proven effective to a certain extent, ongoing research aims to refine and expand these approaches. Potential future directions include:

**7.1. Biomarker Identification:**

Identifying specific biomarkers associated with the development of ifosfamide-induced hematuria could enable early detection and intervention. Biomarkers could also aid in tailoring treatment plans based on individual patient risk profiles.

**7.2. Novel Protective Agents:**

Research efforts are focused on developing novel agents that can more effectively neutralize or mitigate the toxic effects of acrolein on the urothelium. Such agents could potentially enhance the protective effects of mesna and reduce the incidence and severity of hematuria.

**7.3. Personalized Treatment Strategies:**

Advancements in personalized medicine may allow for the customization of ifosfamide dosing and administration based on patient characteristics, genetic factors, and risk factors. This could minimize urological complications while maintaining therapeutic efficacy.

**7.4. Supportive Care Innovations:**

Innovations in supportive care, such as pain management strategies and improved methods for addressing bladder discomfort, could enhance the overall patient experience during ifosfamide treatment.

**8. CONCLUSION:**

Hematuria secondary to ifosfamide administration remains a significant clinical challenge, impacting patient well-being and treatment outcomes. This manuscript has provided an overview of the pathophysiology, risk factors, clinical presentation, and current management strategies for this condition. By integrating preventative measures, symptomatic management, and urologic consultation, healthcare professionals can effectively manage ifosfamide-induced hematuria and optimize patient care. Continued research into underlying mechanisms and innovative interventions is necessary to further enhance treatment strategies and improve patient outcomes.

**Acknowledgments:**

We acknowledge the contributions of healthcare providers, researchers, and patients in advancing our understanding of ifosfamide-induced hematuria and its management.

**Conflict of Interest:**

The authors declare no conflicts of interest related to this manuscript.

**REFERENCES:**

- 1 Brock N , Pohl J, Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur J Cancer Clin Oncol1981;17:1155-63. Google ScholarCrossrefPubMedWorldCat
- 2 Dechant KL , Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs1991;42:428-67. Google ScholarCrossrefPubMedWorldCat
- 3 Kaijser GP , Korst A, Beijnen JH, Bult A, Underberg WJ. The analysis of ifosfamide and its metabolites (review). Anticancer Res1993;13:1311-24. Google ScholarPubMedWorldCat
- 4 Korkmaz A , Topal T, Oter S. Pathophysiological aspects of cyclophosphamide

- and ifosfamide induced hemorrhagic cystitis: implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol2007; 23:303-12. Google ScholarCrossrefPubMedWorldCat
- 5 Brock N , Pohl J, Stekar J. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. J Cancer Res Clin Oncol1981;100:311-20. Google ScholarCrossrefPubMedWorldCat
- 6 Fukuoka M , Negoro S, Masuda N, et al . Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol1991;117:473-8. Google ScholarCrossrefPubMedWorldCat
- 7 Hensley ML , Hagerty KL, Kewalramani T, et al . American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol2009;27:127-45. Google ScholarCrossrefPubMedWorldCat
- 8 Brade WP , Herdrich K, Varini M. Ifosfamide - pharmacology, safety and therapeutic potential. Cancer Treat Rev1985;12:1-47. Google ScholarCrossrefPubMedWorldCat
- 9 Hensley ML , Schuchter LM, Lindley C, et al . American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol1999;17:3333-55. Google ScholarCrossrefPubMedWorldCat
- 10 Corman JM , McClure D, Pritchett R, Kozlowski P, Hampson NB. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen. J Urol2003;169:2200-2. Google ScholarCrossrefPubMedWorldCat
- 11 Hassan Z , Remberger M, Svenberg P, et al . Hemorrhagic cystitis: a retrospective single-center survey. Clin Transplant2007;21:659-67. Google ScholarCrossrefPubMedWorldCat
- 12 Riachy E , Krauel L, Rich BS, et al . Risk factors and predictors of severity score and complications of pediatric hemorrhagic cystitis. J Urol2014;191:186-92. Google ScholarCrossrefPubMedWorldCat
- 13 Droller MJ , Saral R, Santos G. Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology1982;20:256-8. Google ScholarCrossrefPubMedWorldCat
- 14 Matsuo S , Imai E, Horio M, et al . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis2009;53:982-92. Google ScholarCrossrefPubMedWorldCat
- 15 Schwartz GJ , Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am1987;34:571-90.